Phase II study of single agent RAD001 [everolimus] in patients with colon cancer and activating muations in the PI3KCA gene
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 30 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 31 Oct 2006 New trial record.